{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:48:35Z","timestamp":1787726915730,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":1032,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1136\/esmoopen-2018-000364","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T13:07:48Z","timestamp":1531400868000},"page":"e000364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer"],"prefix":"10.1016","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct01871805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01871805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01871805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02604342","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02604342","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02075840","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Socinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Alejandro","family":"Chiappori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Riely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatka","family":"Smoljanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Bordogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Debusk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zeaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2018-000364_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1136\/esmoopen-2018-000364_bb0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2018-000364_bb0020","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2018-000364_bb0025","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0000000000000318","article-title":"Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer","volume":"9","author":"Blackhall","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0030","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","article-title":"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study","volume":"14","author":"Seto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0035","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase ii global study","volume":"34","author":"Ou","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0045","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0050","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2018-000364_bb0055","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/JTO.0000000000000517","article-title":"Symptom and quality of life improvement in LUX-Lung 6: an open-label phase III study of afatinib versus cisplatin\/gemcitabine in asian patients with EGFR mutation-positive advanced non-small-cell lung cancer","volume":"10","author":"Geater","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2018-000364_bb0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2018-000364_bb0070","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0959-8049(01)00127-7","article-title":"Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30","volume":"37","author":"Fayers","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2018-000364_bb0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0080","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","article-title":"Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group","volume":"41","author":"Osoba","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2018-000364_bb0085","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/annonc\/mdw211","article-title":"Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients","volume":"27","author":"Patel","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000364_bb0090","series-title":"EORTC QLQ-C30 reference values","author":"Scott","year":"2008"},{"key":"10.1136\/esmoopen-2018-000364_bb0095","series-title":"Patient-reported outcomes and safety from the phase III ALUR study of alectinib vs chemotherapy in pre-treated ALK+ NSCLC","author":"Mazi\u00e8res","year":"2017"},{"key":"10.1136\/esmoopen-2018-000364_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920322778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920322778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2018-000364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T22:08:21Z","timestamp":1623535701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920322778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"alternative-id":["S2059702920322778"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000364","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000364"}}